Actinium Pharmaceuticals, Inc. current report, 19 June 2020

Business Context and Reporting Period

Company: Actinium Pharmaceuticals, Inc. (ATNM)
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2020
Event: Closing of a previously reported public offering of common stock or pre-funded warrants.

Key Financial Metrics

This filing is a current report regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.

Material Changes

The material change reported is the successful closing of a public offering of common stock (or pre-funded warrants to purchase common stock in lieu thereof) on June 19, 2020.

Guidance, Outlook, and Risks

Management Commentary: The filing references a press release (Exhibit 99.1) for details on the offering but does not include specific guidance, outlook, or risk factors within the text of this 8-K.
Unusual Items: None reported beyond the capital raise event.

Investor Verification Checklist

  • Review the attached press release (Exhibit 99.1) for the specific number of shares/warrants issued and the offering price.
  • Verify the total gross proceeds raised from the offering.
  • Confirm the post-offering share count and any dilution impact.
  • Check subsequent filings (e.g., 10-Q or 10-K) for the utilization of proceeds and updated liquidity position.